A CROI 2019 study suggests the dynamics of HIV proliferation in the viral reservoir might explain why viral load sometimes fails to become undetectable, especially when adherence is good.
M184V Mutation Associated With Increased Risk of Viral Blip but Not Viral Failure With 3TC-Based Dual Therapy
A retrospective analysis presented at CROI 2018 looked at risk of viral rebound in people who switched to lamivudine (Epivir, 3TC)-based dual antiretroviral therapy.
"Overall, we saw improvements for the whole population, suggesting that the efforts to test [and] diagnose HIV infection sooner, start [antiretroviral] treatment earlier and help patients be retained in care and adherent to their treatment are workin...
Among people starting their first antiretroviral therapy regimen, more advanced HIV disease and black race independently predicted severe weight gain through 96 weeks of follow-up.
Paul Sax, M.D., provides a quick rundown of what he considers the most interesting studies presented at this year's Conference on Retroviruses and Opportunistic Infections.
Researchers found that certain factors played an important role in reducing survival among HIV-positive people, including co-infection with hepatitis-causing viruses, excessive intake of alcohol, substance use and tobacco smoking.
Even with current HIV treatment, there are still barriers to care and complications. To help identify and address these obstacles, we asked some leading HIV experts and advocates what they think is the most overlooked issue in HIV care today.
Jennifer Johnsen, M.D., M.P.H., provides a broad update on CROI 2015, including developments in treatment, prevention and cure research.
Smoking marijuana was associated with less HIV testing, but didn't affect a patient's journey toward viral suppression, according to a study presented at CROI 2015.
If a major study found "zero" cases of HIV transmission among mixed-status couples, why did it also find that the risk was higher than zero?